What is Neuronix?
Founded in 2008, Neuronix Medical is dedicated to developing innovative treatments for Alzheimer Disease (AD). The company's core offering, NICE, utilizes a novel, patent-pending technology that combines stimulation of affected brain regions with interlaced cognitive training. This approach aims to induce Long Term Potentiation (LTP), a process linked to learning and memory, with the goal of achieving measurable cognitive improvements in patients within weeks. Neuronix is positioned as a developing medical device company with a vision to provide relief to millions affected by AD worldwide.
How much funding has Neuronix raised?
Neuronix has raised a total of $5.5M across 1 funding round:
Unspecified
$5.5M
Unspecified (2014): $5.5M, investors not publicly disclosed
What's next for Neuronix?
The recent major strategic investment signals a pivotal phase for Neuronix, likely enabling the company to scale its operations, advance its NICE technology through further clinical trials, and potentially expand its market reach. This enterprise-level funding suggests a focus on robust growth and market penetration, positioning Neuronix to solidify its standing in the competitive medical device sector for neurodegenerative disease treatments.
See full Neuronix company page
